ESPE Abstracts (2016) 86 P-P1-550

ESPE2016 Poster Presentations Perinatal Endocrinology P1 (24 abstracts)

Persistent Ketotic Hypoglycemia as an Atypical Presentation of Heterozygous HNF4A Mutation

Julia von Oetting , John Mitchell , Daphné Cloutier & Daphne Yau


McGill University Health Center, Montreal, Quebec, Canada


Background: Heterozygous loss-of-function HNF4A mutations are known to lead to monogenic diabetes, and in infants to macrosomia and hyperinsulinemic hypoglycemia. We are reporting a patient with a heterozygous HNF4A mutation (c.997C>T p.ARG333Cys) presenting with persistent ketotic hypoglycemia.

Case report: In a 38 weeks’ gestation infant (birth weight 4.1 kg, pregnancy complicated by insulin-requiring gestational diabetes), hypoglycemia developed in the first hours of life. Initially diagnosed with hyperinsulinemic hypoglycemia due to gestational diabetes, treatment with diazoxide 7.5 mg/kg/day was initiated. Hyperglycemia and severe signs of fluid overload requiring intensive care developed and treatment was discontinued. During a lengthy hospitalization, high insulin and concurrently low C-peptide levels in the context of hypoglycemia were suggestive of exogenous insulin administration. A congenital hyperinsulinism genetic panel showed a likely pathogenic variant of HNF4A, but was not thought to be relevant in the context of suspected Munchausen by proxy. At age 7 months, the patient presented to our hospital with recurrent ketotic hypoglycemia. Hypoglycemia observed as soon as 1 h post-prandially persisted while hospitalized and while wearing a continuous glucose monitor at home. Critical samples during hypoglycemia showed appropriately low levels of insulin (1.1–5.2 pmol/l), and elevated ketone levels 1.30–2.30 mmol/l). Cortisol and growth hormone were 667 nmol/l and 4.2 mcg/l (maximum value), respectively. Glycemia rose <1.7 mmol/l in response to glucagon administration. Acylcarnitine profile, glycogen storage disease genetic panel and toxicology screen were negative. Therapeutic trials with corn starch and Octreotide failed. Despite prior side effects, Diazoxide at a dose of 5 mg/kg/day was retrialed in combination with hydrochlorothiazide, and hypoglycemia resolved.

Conclusion: Heterozygous HNF4A mutations may present as ketotic hypoglycemia, and laboratory investigations may not suggest hyperinsulinism. We considered dysregulated insulin secretion, down-regulation of GLUT2 as a result of the known HNF4A mutation vs. an additional condition predisposing to hypoglycemia as possible mechanism to explain this presentation.

Volume 86

55th Annual ESPE (ESPE 2016)

Paris, France
10 Sep 2016 - 12 Sep 2016

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.